Late Breaking Abstract - Mepolizumab treatment in children and adolescents with severe eosinophilic asthma (CASAM)-A real-world study:initial analysis

<bold>Introduction:</bold> Clinical trials have shown efficacy of mepolizumab in reducing exacerbations in severe eosinophilic asthma, but real-world clinical practice data on children and young people (CYP) with severe asthma are lacking. We assessed the effectiveness and safety of mepolizumab prescribed for CYP with severe asthma in the real world. <bold>Methods:</bold> CASAM is a multinational, multicentre, observational cohort study, collected data from routine healthcare visits. CYP prescribed mepolizumab for severe asthma with 12 months of relevant medical history pre-mepolizumab (collected retrospectively & prospectively) were enrolled. An initial analysis of data from early starters who completed six months of follow-up was conducted. The primary objective was to compare the rate of clinically significant exacerbations (exacerbation requiring systemic corticosteroids and/or ED visit and/or hospital admission) before and after mepolizumab and change in asthma control. Treatment-related adverse events were reported. <bold>Results:</bold> Overall, 85 CYP were included with a mean age of 11.17(SD ± 2.86) years at mepolizumab initiation. The proportion of CYP experiencing clinically significant exacerbations reduced at six-month follow-up (P<0.001) with improvement in asthma control as measured by ACT score (P<0.01). Rates of clinically significant exacerbations reduced by 45.1% from 3.7 exacerbations per person per year pre-treatment to 2.03 exacerbations per person per year. No new safety signals were reported. <bold>Conclusion:</bold> These data demonstrate that mepolizumab is effective in CYP in real-world settings, significantly reducing exacerbations and improving asthma control.

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa2245
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Late Breaking Abstract - Mepolizumab treatment in children and adolescents with severe eosinophilic asthma (CASAM)-A real-world study:initial analysis

Ana Martinez Canavate, José Valverde‐Molina, Ana Díez-Izquierdo, Olga de la Serna Blázquez et al.
Asthma and respiratory diseases
article

Late Breaking Abstract - Mepolizumab treatment in children and adolescents with severe eosinophilic asthma (CASAM)-A real-world study:initial analysis

Ana Martinez Canavate, José Valverde‐Molina, Ana Díez-Izquierdo, Olga de la Serna Blázquez, Silvia Castillo, Paula Corcuera, C. Gracia, Katharine C. Pike, Chinedu Nwokoro, A R Turnbull, Alicia Callejón Callejón, James Cook, Laura Valdesoiro Navarrete, Latika Gupta, Mirella Gáboli, A. López Neyra, Jaime Lozano Blasco, Juan Navarro Morón, Clare Murray, Inés de Mir Messa, Prasad Nagakumar, Atul Gupta, Pilar Caro Aguilera, Álvaro Gimeno Díaz de Atauri, Yolanda Aliaga
article en

Abstract

<bold>Introduction:</bold> Clinical trials have shown efficacy of mepolizumab in reducing exacerbations in severe eosinophilic asthma, but real-world clinical practice data on children and young people (CYP) with severe asthma are lacking. We assessed the effectiveness and safety of mepolizumab prescribed for CYP with severe asthma in the real world. <bold>Methods:</bold> CASAM is a multinational, multicentre, observational cohort study, collected data from routine healthcare visits. CYP prescribed mepolizumab for severe asthma with 12 months of relevant medical history pre-mepolizumab (collected retrospectively & prospectively) were enrolled. An initial analysis of data from early starters who completed six months of follow-up was conducted. The primary objective was to compare the rate of clinically significant exacerbations (exacerbation requiring systemic corticosteroids and/or ED visit and/or hospital admission) before and after mepolizumab and change in asthma control. Treatment-related adverse events were reported. <bold>Results:</bold> Overall, 85 CYP were included with a mean age of 11.17(SD ± 2.86) years at mepolizumab initiation. The proportion of CYP experiencing clinically significant exacerbations reduced at six-month follow-up (P<0.001) with improvement in asthma control as measured by ACT score (P<0.01). Rates of clinically significant exacerbations reduced by 45.1% from 3.7 exacerbations per person per year pre-treatment to 2.03 exacerbations per person per year. No new safety signals were reported. <bold>Conclusion:</bold> These data demonstrate that mepolizumab is effective in CYP in real-world settings, significantly reducing exacerbations and improving asthma control.

Hospital Sant Joan de Déu Barcelona (ES), Great Ormond Street Hospital (GB), Hospital Universitario La Paz (ES), Royal London Hospital (GB), Bristol Royal Hospital for Children (GB), Research Institute Hospital 12 de Octubre (ES), Hospital Universitario Nuestra Señora de Candelaria (ES), Hospital Clínico Universitario de Valencia (ES), Birmingham Women's Hospital (GB), Biogipuzkoa Health Research Institute (ES), Birmingham Children's Hospital (GB), Hospital Universitario 12 De Octubre (ES), Hospital Regional Universitario de Málaga (ES), Hospital Infantil Universitario Niño Jesús (ES), Hospital Universitario Miguel Servet (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital de Sabadell (ES), Vall d'Hebron Hospital Universitari (ES), Donostiako Unibertsitate Ospitalea (ES), Santa Lucía University General Hospital (ES), Hospital Universitario Virgen del Rocío (ES), King's College Hospital (GB), Hospital Universitari Germans Trias i Pujol (ES), Royal Manchester Children's Hospital (GB), University College London (GB)
Openalex Percentile: Top 72%
Asthma and respiratory diseases
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.